ALK rearrangent in pulmonary sarcomatoid carcinoma: a retrospective study of the real world

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Cancer Biology
Thoracic Malignancies
Presenter You-cai Zhu
Citation Annals of Oncology (2018) 29 (suppl_9): ix113-ix120. 10.1093/annonc/mdy441
Authors Y. Zhu1, C. Xu2, W. Wang3, M. Fang3, W. Zhuang4, Q. Zhang2, Z. Gong5, Y. Chen2, G. Chen2, T. Lv6, Y. Song6
  • 1Thoracic Disease Diagnosis And Treatment Center, Zhejiang Rongjun Hospital, 314000 - Jiaxing/CN
  • 2Pathology, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 3Chemotherapy, Zhejiang Cancer Hospital, 310022 - Hangzhou/CN
  • 4Medical Thoracic Oncology, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 5None, Yunying Medicine, 201601 - Shanghai/CN
  • 6Respiratory Medicine, Jinling Hospital, 210002 - Nanjing/CN



Pulmonary sarcomatoid carcinoma (PSC) is a recognized category of highly aggressive and poorly differentiated non-small-cell lung carcinoma (NSCLC), with five different subtypes: pleomorphic, spindle, giant cell, carcinosarcoma, and pulmonary blastoma. Although uncommon (0.1% to 0.4% of all pulmonary malignancies), their clinical importance is underscored by poorer prognosis and higher rate of resistance to conventional chemotherapy than other NSCLCs. And the incidence of anaplastic lymphoma kinase (ALK) rearrangement in PSC is controversial. The aim of this study was to reveal the reliable frequency and the clinical-pathologic characteristics of PSC with ALK rearrangement in Chinese population.


A total of 52 patients with PSC were recruited between September 2007 and December 2017. The status of ALK rearrangement was detected by reverse transcriptionpolymerase chain reaction(RT-PCR).


Of this study, three patients were identified with ALK rearrangement in Chinese population (5.77%, 3/52). They were all were pulmonary pleomorphic carcinoma (PPC). PSCs in former or current smokers were more likely to harbor ALK rearrangement than those in non-smoker (P < 0.05).


The incidence rates of ALK rearrangement in PSC in the Chinese population are similar to those of other subtypes of NSCLC. PSCs in former or current smokers are more often to harbor ALK rearrangement. ALK inhibitors may serve as an effective treatment for ALK-rearranged PSC.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

You-Cai Zhu.


Has not received any funding.


All authors have declared no conflicts of interest.